Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trimetrexate

Drug Profile

Trimetrexate

Alternative Names: CI 898; JB 11; Neutrexin; NSC 249008; NSC 328564; NSC 352122; Trimetrexate glucuronate

Latest Information Update: 18 Jan 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class Antineoplastics; Antiprotozoals; Quinazolines
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Pneumocystis pneumonia
  • Discontinued Bladder cancer; Breast cancer; Cancer; Cervical cancer; Colorectal cancer; Gastric cancer; Leukaemia; Lung cancer; Non-small cell lung cancer; Pancreatic cancer; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 14 Jan 2010 Biovitrum has merged with Swedish Orphan to form Swedish Orphan Biovitrum
  • 19 Jun 2007 MedImmune has been acquired by AstraZeneca
  • 05 Jun 2003 Beaufour-Ipsen is now called Ipsen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top